2026 ASH®
Annual Meeting & Exposition December 12-15, 2026 ▪ New Orleans, Louisiana

Paper Details

Abstracts, authors, affiliations, and disclosures.

Saturday, December 12, 2026
05:30 p.m. - 07:30 p.m.
MCCNO - Hall F
Technology and Procedures, Assays, Imaging, Omics Technologies, Bioinformatics, Cell Expansion, Computational Biology, Treatment Considerations, Drug Development, Biological Therapies, Transplantation, Gene Therapy, Adverse Events, Biological Processes, Pathogenesis, Genomics, Hematopoiesis, Immune Mechanism, Metabolism, Molecular Biology, Diseases, Genetic Disorders, Hemoglobinopathies, Sickle Cell Disease, Research, Fundamental Science, Translational Research, Clinical Research, Epidemiology, Study Population, Human, Adult, Pediatric, Animal Model
PAPER

1152 Cryo-electron microscopy structure of the sickle hemoglobin fiber at 1.9 Å resolution

Olivia Lambertson, Jianghai Zhu, PhD2, Phil Cruz, PhD3, Forrest Hoyt, MS4, Mamadou Sangare, PhD5, Vinod Nair, PhD6, William A. Eaton, MD, PhD7, Hans Ackerman, MD, DPhil8
1 National Institutes of Health, Bethesda, Maryland, United States, National Institutes of Health, Bethesda, Maryland, United States
2 National Institutes of Health, Bethesda, Maryland, United States
3 National Institutes of Health, Bethesda, Maryland, United States
4 National Institutes of Health, Bethesda, Maryland, United States
5 National Institutes of Health, Bethesda, Maryland, United States, National Institutes of Health, Bethesda, Maryland, United States
6 National Institutes of Health, Bethesda, Maryland, United States
7 National Institutes of Health, Bethesda, Maryland, United States
8 National Institutes of Health, Bethesda, Maryland, United States

Sickle cell disease (SCD) is a genetic disease caused by a glutamic acid to valine substitution at position six of the beta subunits of hemoglobin (βGlu6Val). This mutation results in deoxygenated sickle hemoglobin (HbS) polymerizing and forming fibers that distort, stiffen, and hemolyze red blood cells (RBCs) causing anemia, episodes of severe pain, and organ damage in over 8 million people worldwide. A previous model of the HbS fiber structure was developed by integrating data from transmission electron micrographs, a deoxy HbS crystal structure, and mutational studies. However, it lacked the resolution and accuracy necessary for virtual drug screening or design of polymerization inhibitors. Thus, we sought to determine a near-atomic resolution structure of the HbS fiber using cryo-electron microscopy (cryo-EM).

HbS was purified from SCD patient RBCs and concentrated to 260 mg/mL.  Polymerization kinetics of samples were determined spectrophotometrically by measuring the increase in optical density that occurs when growing fibers scatter light. The timing of sampling and vitrifying the HbS solution was guided by the polymerization kinetics. Cryo-EM grids were prepared using a vitrobot (FEI) in a nitrogen purged, deoxygenated glovebox. Successful grids were produced by sampling in the middle of the delay period and following with a buffer rinse to dilute but not dissolve the nascent fibers. Data were collected on a Krios G4 cryo-transmission electron microscope. Helical reconstruction was performed in CryoSPARC, with further refinement performed in Phenix to obtain the final structure.

We report a structure with an average resolution of 1.9 Å. The structure consists of seven helically twisted double strands which form a fourteen-stranded fiber. The repeating asymmetrical unit consists of fourteen tetramers, or one complete layer, and has a twist of 7.9°. Within a layer, there are 43 unique interaction patches that hold a layer together, with an additional 62 interaction patches between layers. This structure not only confirms well-known interactions between βVal6 and the hydrophobic residues βAla70, βAsp73, βPhe85, and βLeu88, but also reveals recurring axial contacts that may be promising targets for inhibiting fiber extension.

Though the arrangement of the HbS molecules in the fiber is similar to Cretegny & Edelstein’s 1993 14-stranded model, the new data provide substantial revisions, specifically regarding the nature of contacts between deoxy HbS tetramers and the absence of bilateral symmetry within one layer of the fiber. This new structure will accelerate the discovery of polymerization inhibitors for the treatment of sickle cell disease through virtual drug screenings and de novo drug designs that target the newly discovered contact patches within the fibers.

Olivia Lambertson: No relevant conflicts of interest to declare.